Q2 2026 Holdings
Filed 2026-08-13 | 113 holdings | $2.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $132.7M | 3,750,000 | 6.0% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $131.0M | 987,000 | 5.9% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $113.6M | 1,279,134 | 5.1% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $96.3M | 1,595,000 | 4.4% |
| Erasca Inc(ERAS) | COM | 29479A108 | $96.2M | 5,250,000 | 4.3% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $69.3M | 650,000 | 3.1% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $61.9M | 185,000 | 2.8% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $58.9M | 1,125,000 | 2.7% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $56.2M | 590,000 | 2.5% |
| Anaptysbio Inc(ANAB) | COM | 032724106 | $55.8M | 826,109 | 2.5% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $53.6M | 2,900,000 | 2.4% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $46.9M | 550,000 | 2.1% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $46.8M | 250,000 | 2.1% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $44.0M | 330,000 | 2.0% |
| First Tracks Biotherapeutics(TRAX) | ORD SHS | 337185102 | $40.9M | 2,032,012 | 1.8% |
| Dianthus Therapeutics Inc(DNTH) | COM | 252828108 | $39.0M | 400,000 | 1.8% |
| Sutro Biopharma Inc(STRO) | COM SHS | 869367201 | $38.9M | 1,172,487 | 1.8% |
| Moderna Inc(MRNA)Put | COM | 60770K107 | $35.0M | 500,000 | 1.6% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $34.0M | 275,000 | 1.5% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $33.6M | 1,800,172 | 1.5% |
| Moderna Inc(MRNA)Call | COM | 60770K107 | $33.3M | 475,000 | 1.5% |
| ARK ETF TR(ARKG)Call | GENOMIC REV ETF | 00214Q302 | $31.5M | 750,000 | 1.4% |
| Ovid Therapeutics Inc(OVID) | COM | 690469101 | $27.3M | 10,144,562 | 1.2% |
| Lexeo Therapeutics Inc(LXEO) | COM | 52886X107 | $27.0M | 5,807,611 | 1.2% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $26.0M | 700,000 | 1.2% |
| Belite BIO Inc(BLTE) | SPONSORED ADS | 07782B104 | $25.4M | 165,000 | 1.1% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $25.4M | 500,000 | 1.1% |
| Forte Biosciences Inc(FBRX) | COM NEW | 34962G208 | $24.3M | 1,145,391 | 1.1% |
| ELI Lilly & Co(LLY)Call | COM | 532457108 | $24.0M | 20,000 | 1.1% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $23.5M | 967,620 | 1.1% |
| Alto Neuroscience Inc(ANRO) | COM SHS | 02157Q109 | $22.4M | 850,000 | 1.0% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $21.5M | 40,000 | 1.0% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $21.1M | 172,125 | 1.0% |
| Mineralys Therapeutics Inc(MLYS) | COM | 603170101 | $20.2M | 750,000 | 0.9% |
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $19.6M | 1,050,000 | 0.9% |
| Sagimet Biosciences Inc(SGMT) | COM SER A | 786700104 | $19.3M | 2,497,864 | 0.9% |
| Jade Biosciences Inc(JBIO) | COM NEW | 008064206 | $18.7M | 840,350 | 0.8% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $17.4M | 450,000 | 0.8% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $17.0M | 300,000 | 0.8% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $15.9M | 875,760 | 0.7% |
| Savara Inc(SVRA) | COM | 805111101 | $15.5M | 2,512,153 | 0.7% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $14.9M | 400,000 | 0.7% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $14.4M | 4,214,582 | 0.6% |
| Odyssey Therapeutics Inc(ODTX) | COMMON STOCK | 67613T104 | $14.3M | 766,346 | 0.6% |
| Cogent Biosciences Inc | NOTE 1.625%11/1 | 19240QAA0 | $13.7M | $11,000,000 | 0.6% |
| Omeros Corp(OMER)Put | COM | 682143102 | $13.4M | 1,411,300 | 0.6% |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | $13.3M | 1,250,000 | 0.6% |
| Equillium Inc(EQ) | COM | 29446K106 | $13.1M | 4,100,000 | 0.6% |
| Alkermes PLC(ALKS)Call | SHS | G01767105 | $13.1M | 250,000 | 0.6% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $12.7M | 148,013 | 0.6% |